Analytical Data
-
Gene name
Cxcl17
- Application
-
Alternative Names
Cxcl17；VCC1；C-X-C motif chemokine 17
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q6UXB2
-
Expression Region
22-119aa
-
AA Sequence
MGSSHHHHHH SSGLVPRGSH MSSLNPGVAR GHRDRGQASR RWLQEGGQEC ECKDWFLRAP RRKFMTVSGL PKKQCPCDHF KGNVKKTRHQ RHHRKPNKHS RACQQFLKQC QLRSFALPL
-
Molecular Weight
14 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
CXCL17, a chemokine belonging to the CXC family, has garnered significant attention in recent years due to its potential role in immunological responses and its involvement in various diseases. Expressed in various tissues, CXCL17 is known for its ability to bind receptors on immune cells, influencing their migration and activation. Research has shown that CXCL17 plays a crucial role in inflammation, particularly in responses associated with respiratory and autoimmune diseases. Additionally, its expression has been linked to cancer progression, suggesting that it may have dual roles in promoting or inhibiting tumor development depending on the context. The study of recombinant CXCL17 protein has become vital for understanding its biological functions and mechanisms of action. Researchers aim to investigate its therapeutic potential, exploring how recombinant versions of the protein can be used in drug development for disease treatment. The ongoing exploration of CXCL17 not only enhances our comprehension of immune system regulation but also opens new avenues for targeted therapies in conditions where CXCL17 is dysregulated. Thus, the development and characterization of recombinant CXCL17 protein are essential for advancing both basic science and clinical applications in immunology and oncology.
